112 related articles for article (PubMed ID: 16735697)
21. [Acneiforme rash in woman with pulmonary adenocarcinoma].
Navarro Martín M; Rodríguez Sánchez C; Delgado Fernández C; Mezquita Pérez L; Cruz Hernández JJ
Rev Clin Esp; 2008 May; 208(5):251-2. PubMed ID: 18457638
[No Abstract] [Full Text] [Related]
22. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
[No Abstract] [Full Text] [Related]
23. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
24. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
Bragg J; Pomeranz MK
Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Lind JS; Lagerwaard FJ; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Kim JE; Lee DH; Choi Y; Yoon DH; Kim SW; Suh C; Lee JS
Lung Cancer; 2009 Sep; 65(3):351-4. PubMed ID: 19157632
[TBL] [Abstract][Full Text] [Related]
27. [Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Cai Y; Wang WL; Xu B; Zhu GY; Zhang SW
Ai Zheng; 2006 Nov; 25(11):1419-22. PubMed ID: 17094913
[TBL] [Abstract][Full Text] [Related]
28. [Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis].
Huang GJ; Fang DK; Cheng GY; Zhang DC
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):62-4. PubMed ID: 16737625
[TBL] [Abstract][Full Text] [Related]
29. Recovery from carcinomatous meningitis by erlotinib.
Ohara G; Kagohashi K; Kurishima K; Kawaguchi M; Nakayama H; Satoh H
Onkologie; 2011; 34(7):394-5. PubMed ID: 21734429
[No Abstract] [Full Text] [Related]
30. Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy.
Bischof M; Debus J; Herfarth K; Muley T; Kappes J; Storz K; Hoffmann H
Strahlenther Onkol; 2007 Dec; 183(12):679-84. PubMed ID: 18040612
[TBL] [Abstract][Full Text] [Related]
31. Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
Huang YJ; Liu SF; Wang CJ; Huang MY
Lung Cancer; 2008 Mar; 59(3):407-10. PubMed ID: 17804114
[TBL] [Abstract][Full Text] [Related]
32. Management Difficulties in a Patient with EGFR-mutation Positive Lung Adenocarcinoma and Cerebral Metastases.
Cruz P; de Lujan L; de Castro J
Arch Bronconeumol; 2017 Jan; 53(1):37-38. PubMed ID: 27712850
[No Abstract] [Full Text] [Related]
33. Erlotinib-induced scalp perifolliculitis.
Rallis E; Petronic-Rosic V; Korfitis C
Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Ong CK; Tan WC; Chan LC; Abdul Razak M
Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
[TBL] [Abstract][Full Text] [Related]
35. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Chang CC; Chi KH; Kao SJ; Hsu PS; Tsang YW; Chang HJ; Yeh YW; Hsieh YS; Jiang JS
Lung Cancer; 2011 Aug; 73(2):189-94. PubMed ID: 21247653
[TBL] [Abstract][Full Text] [Related]
36. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
38. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Böker B; Lüders H; Grohé C
Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328
[TBL] [Abstract][Full Text] [Related]
40. Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Kudo K; Fujiwara K; Tsushima M; Mizuta M; Matsuo K; Yonei T; Sato T
Acta Oncol; 2011 Jan; 50(1):146-8. PubMed ID: 20843170
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
